Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivastigmine tartrate
Drug ID BADD_D01956
Description Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Indications and Usage For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Marketing Status Prescription; Discontinued
ATC Code N06DA03
DrugBank ID DB00989
KEGG ID D02558
MeSH ID D000068836
PubChem ID 6918078
TTD Drug ID D0WY5Q
NDC Product Code 60687-574; 55111-355; 62756-146; 62756-148; 62756-145; 75834-135; 51991-794; 33342-090; 49706-1826; 65862-650; 51991-795; 71209-012; 71209-015; 0904-6587; 62704-0122; 33342-092; 65862-651; 46708-066; 75834-134; 55111-354; 50379-0012; 33342-089; 46708-873; 71209-014; 65862-649; 65862-648; 62756-147; 0904-7107; 62756-136; 65372-1152; 55111-352; 55111-066; 71209-013; 55111-353; 65862-612; 75834-136; 72241-011; 33342-091; 53104-7571; 46708-064; 72241-013; 51991-796; 72241-012; 75834-133; 51991-793; 72241-014; 46708-065; 70518-3012; 46708-063
Synonyms Rivastigmine | (S)-N-Ethyl-3-((1-dimethyl-amino)ethyl)-N-methylphenylcarbamate | RivastigmineTartrate | Rivastigmine Hydrogen Tartrate | Hydrogen Tartrate, Rivastigmine | Tartrate, Rivastigmine Hydrogen | Exelon | ENA 713 | 713, ENA | SDZ ENA 713 | 713, SDZ ENA | ENA 713, SDZ | ENA-713 | ENA713
Chemical Information
Molecular Formula C18H28N2O8
CAS Registry Number 129101-54-8
SMILES CCN(C)C(=O)OC1=CC=CC(=C1)C(C)N(C)C.C(C(C(=O)O)O)(C(=O)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
AstheniaCholinesteraseP06276T99799Not Available
DiarrhoeaCholinesteraseP06276T99799Not Available
DizzinessCholinesteraseP06276T99799Not Available
VomitingCholinesteraseP06276T99799Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Dermatitis psoriasiform23.03.14.004--Not Available
Restless legs syndrome17.02.07.008; 15.05.03.012--Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Congenital eye disorder06.08.03.011; 03.01.01.002--Not Available
Angiopathy24.03.02.007--Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output increased13.13.03.002--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Freezing phenomenon17.01.05.006--Not Available
Bacterial infection11.02.01.005--Not Available
Bladder disorder20.03.01.002--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.01.01.003--Not Available
Connective tissue disorder15.06.01.006--Not Available
Eyelid disorder23.03.03.028; 06.08.03.010--Not Available
Infestation11.09.01.001; 23.09.05.001--Not Available
Inflammation08.01.05.007--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction17.02.10.004--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
Ill-defined disorder08.01.03.049--Not Available
Inner ear disorder04.04.02.002--Not Available
Lacrimal disorder06.08.02.005--Not Available
Parkinson's disease17.01.05.010--Not Available
Red blood cell abnormality01.07.02.006--Not Available
Blood disorder01.05.01.004--Not Available
The 14th Page    First    Pre   14 15    Next   Last    Total 15 Pages